Skip to main content

PVM Researcher Helps Lead Purdue Effort to Take ‘Accelerator’ off Aggressive Prostate and Other Deadly Tumors

Purdue Veterinary Medicine Associate Professor of Basic Medical Sciences Marxa Figueiredo helped lead a Purdue research team studying ways to make prostate cancer less lethal by making it less aggressive. Prostate cancer is ranked as the second most common and second most fatal cancer among men by the American Cancer Society.

Dr. Figueiredo pictured with student in lab

Purdue University associate professor Marxa Figueiredo, right, worked with students as she helped lead a team developing an anti-cancer drug with potential to help people and animals.

The Purdue team has developed a drug to target the laminin receptor (37/67 LR), a membrane protein that, when overexpressed, can promote the growth of cancer cells and tumors. The researchers say it also could help fight other types of aggressive cancers, including pancreatic, colon, liver, and breast.

“We are trying to take cancer’s foot off the accelerator by targeting this receptor,” said Dr. Figueiredo. Purdue’s drug binds to the laminin receptor and cuts its ability to help tumors grow and to communicate with blood vessels, which are the lifeblood for cancer cells and tumors. The Purdue compound mimics anti-proliferative and anti-angiogenesis pathways to inhibit cancer cell viability, proliferation, and migration as well the formation of new blood vessels.

new compound pictured

This image shows two poses for a new compound, discovered at Purdue University, docking and targeting the laminin receptor protein for cancer therapy.

The work also aligns with Purdue’s Giant Leaps celebration, acknowledging the University’s global advancements made in health, longevity, and quality of life as part of Purdue’s 150th anniversary. This is one of the four themes of the yearlong celebration’s Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues. Solutions such as this drug are also a focus of Purdue’s Discovery Park District.

The Purdue approach is unique because it provides a single drug to perform multiple functions in cancer treatment. The drug also shows promise for treating similar cancers in pets. “It is incredibly rewarding and exciting to potentially provide new options for people and for animals dealing with aggressive tumors,” Dr. Figueiredo said.

Dr. Figueiredo worked with her former graduate student, Sam Umbaugh, to develop this drug. She is currently collaborating with Dr. Herman Sintim, Purdue’s Drug Discovery Professor of Chemistry, to create different versions of the drug that are more effective against various types of cancers.  Click here to read a complete news release about the research.

Writer(s): Chris Adam, cladam@prf.org; Kevin Doerr | pvmnews@purdue.edu

Recent Stories

“Paws Up” for Jennifer Danaher – brought to you by the PVM Wellness Committee

This week we express our gratitude to Jennifer Danaher, who is department secretary for Veterinary Clinical Sciences.

‘Purdue Pursuits’: A PVM angle on Purdue’s teaching and learning reading groups

Crafting meaningful and engaging course experiences has been at the top of Dielson Vieira’s mind ever since he joined the Purdue University College of Veterinary Medicine’s faculty in 2024. As a clinical assistant professor in the Department of Basic Medical Sciences, Vieira is already adept at applying innovative teaching practices to classroom environments, but that doesn’t stop him from seeking out new ideas, approaches and perspectives — insights he gains through outlets like Purdue’s teaching and learning reading groups.

Top tier biology journal publishes PVM study that unlocks secrets of a drug-resistant fungal pathogen, which causes serious infections in humans

Though the name “Candida auris” is far from a household term, public health experts know it well because the multi-drug-resistant fungal pathogen, which causes serious human infections, has been classified as an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Threats Report (2019). Dr. Shankar Thangamani, Associate Professor of Microbiology and University Faculty Scholar in the Purdue University College of Veterinary Medicine’s Department of Comparative Pathobiology, is researching C. auris, aided by a 2.4 million grant from the National Institutes of Health (NIH). New research findings, just published in Nature Microbiology, show how C. auris adapts and evades the immune system.

In Print: ‘Translational Research Methods for Tauopathies’

A just-published 300-page volume edited by Jessica Fortin, Purdue assistant professor in the College of Veterinary Medicine’s Department of Basic Medical Sciences, provides a significant new resource for researchers studying a group of neurodegenerative diseases known as tauopathies. “Translational Research Methods for Tauopathies” provides detailed protocols intentionally selected to serve as a basis for research laboratories seeking to further treatments for such debilitating neurodegenerative diseases as Alzheimer’s and chronic traumatic encephalopathy (CTE).

It’s Almost Here!

Though the annual Purdue Veterinary Conference is almost upon us, there’s still time to register and take advantage of this time-honored College of Veterinary Medicine fall tradition that combines excellent continuing education with fun opportunities for reconnecting with colleagues and classmates, networking, and learning about the latest veterinary trends and products. The 2026 Purdue Veterinary Conference takes place September 23–26 on the Purdue University campus. The annual event has something for everyone, from veterinarians to veterinary technicians, faculty, staff and students.